This page contains a Flash digital edition of a book.
COMMENT


SINCE THE BREXIT RESULT IN JUNE, THERE HAS BEEN SOME CONFUSION OVER THE PROGRESS AND POTENTIAL IMPACT OF THE FALSIFIED MEDICINES DIRECTIVE (FMD), BUT JEREMY MAIN, MANAGING DIRECTOR OF ALLIANCE HEALTHCARE UK AND CHAIR OF THE HEALTHCARE DISTRIBUTION ASSOCIATION (HDA), BELIEVES THAT THE COUNTDOWN TO FMD IS MOST DEFINITELY ON....


FALSIFIED MEDICINES


DIRECTIVE: THE CLOCK IS TICKING


Whilst proposals for a hub-and- spoke prescription fulfi lment model appear to have been pushed onto the back burner, the implementation of the Falsifi ed Medicines Directive (FMD) is really starting to cook on gas. This affects everyone within the pharmaceutical supply chain and is a transformational change to current systems and processes.


You may be tempted to believe FMD will disappear following the EU referendum, but no one should bury their head in the sand; FMD is already incorporated into UK legislation and is certain to happen. With the legislation becoming effective 9 February 2019, the countdown is on for the pharmaceutical industry to comply with the enhanced security requirements.


With increasing fears, concerns and instances of counterfeit medicines entering the pharmaceutical supply chain, these changes should be welcomed even if they don’t come cheaply.


COLLECTIVE RESPONSIBILITY


Previously, I’ve encouraged all parties to take a holistic view of the industry. FMD is a prime example of an issue affecting all stakeholders and needs to be considered by


24 - SCOTTISH PHARMACIST


manufacturers, wholesalers and dispensers with an aligned approach. The legislation requires prescription medicines for sale to carry a unique and randomised serial number encoded in a 2D-barcode and a visible anti-tampering device.


Manufacturers will be responsible for uploading the serial numbers to a system of national databases linked by a European hub and country- based national data repositories will allow verifi cation at different times and fi nal decommissioning when each pack is dispensed to a patient.


At each stage of the supply chain, the product will be inspected to ensure it hasn’t been tampered with, has not previously been dispensed and that the packaging is intact. Additionally, Goods Distribution Practice (GDP) guidelines will require the individual product to be scanned to record the batch number and expiry date. This check will indicate whether the product is authentic and bring up information such as whether the product has been subject to a recall.


These actions to be carried out across the pharmaceutical supply chain are vital to its integrity and minimise the opportunity for the original product to be replaced with a counterfeit.


FMD TO INCREASE PATIENT SAFETY


I wholeheartedly support the objective of FMD to implement end-to-end verifi cation of the medicines supply chain for all prescription medicines, to not only enhance patient safety, but also provide greater confi dence in the integrity and quality of medicines prescribed. To ensure its successful implementation, FMD will require signifi cant investment both in fi nancial terms and a commitment of time and resource. As one of the UK’s leading pharmaceutical wholesalers, we’ll continue to work with regulators, stakeholder bodies, our manufacturer partners and pharmacy customers to ensure all participants in the medicines supply chain are ready to safely implement the processes for medicines authentication in time.


FMD AT A GLANCE


The FMD followed on from an EU Council Directive from 2011 and is intended to reduce the occasions on which falsifi ed medicines enter the legitimate supply chain.


The directive will affect any medicine product with a false representation of:


* its identity, including its packaging and labelling, its name or its composition as regards any of the ingredients including excipients and the strength of those ingredients


* its source, including its manufacturer, its country of manufacturing, its country of origin or its marketing authorisation holder, or


* its history, including the records and documents relating to the distribution channels used


TRANSFORMATIONAL CHANGE


February 2019 may seem a long way off, but don’t underestimate the scale of change required and in reality, we have less than two years to be ready and to develop, test and input new systems and working practices. I’d encourage everyone to familiarise themselves with the requirements and start collective discussions with stakeholders now! I have no doubt the change will be diffi cult and will come at a price, but I believe the long-term benefi ts far outweigh the short term challenges. Given that all of us either take some form of medicine or have family or friends who are dependent on medication, it may be in our best interests to deliver this solution for the benefi t of all. •


In February, details of the safety features, which set out obligations on all of those in the supply chain were published, and the UK now has three years to implement them.


These safety features include a 2D bar code with a unique identifi er and tamper evident packaging: measures which will affect all prescription medicines (unless they’re exempted).


The unique identifi er features:


* a sequence of alpha-numeric or numeric characters given to the individual pack


* a code allowing identifi cation of the name


* common name, pharmaceutical form and strength as a minimum


* reimbursement information if required by MS,


* batch number, and * expiry date


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64